Back to Equities

LYB

LyondellBasell Industries N.V.
Materials · Specialty & Commodity Chemicals
Gravy Gauge
Is this revenue durable?
Stress Scanner
What breaks under stress?
Myth Meter
Is sentiment detached from reality?
Fugazi Filter
Are the numbers trustworthy?
Roadkill Radar
Is the market missing something?
Moat Mapper
Is the advantage durable?
Insider Investigator
What are insiders telling us?
Black Swan Beacon
What could go catastrophically wrong?
8
Lenses Applied
14
Signals Analyzed
8
Debates Resolved
7
Forecast Markets
The Central Question
"A loud tape narrative ran LYB +40% from $57 (Feb 22, 2026) to $80.56 (Mar 31), now $73.13 (Apr 15). The Q4 2025 earnings call has zero Iran/Hormuz commentary and management explicitly telegraphs 'dividend recalibration' for a February 2026 Board meeting. Access Industries sold 850,000 shares mid-rally at $67-69. At $73, is this a cycle trough turning at ~7-8x mid-cycle EBITDA, or is a 15-20% structural-decline tail being priced as a 25-30% bull case?"

LyondellBasell is a top-5 global chemicals company with a Gulf Coast ethane feedstock cost advantage, top-tier positions in polyethylene, polypropylene, oxyfuels, and acetyls, plus a proprietary catalyst and chemical-recycling technology platform. FY2025 brought net sales $30.15B (-9.7% YoY), a GAAP net loss of $(738)M against non-GAAP EBITDA of $2.5B, a $972M goodwill impairment plus $279M other impairments, and a 7% headcount reduction to 18,700. Four European assets are divesting in Q2 2026. Cash from operations was $2.3B with 95% cash conversion for a fourth consecutive year. The Value Enhancement Program over-delivered ($1.1B vs. $1.0B target) and was raised to $1.5B by 2028. The Cash Improvement Plan over-delivered ($800M vs. $600M target) and aims at a cumulative $1.3B through 2026. CEO Peter Vanacker remains in place.

Executive Summary

Cross-lens roll-up assessment

LyondellBasell sits at a cycle trough of analytically useful importance. Every committee lens finds the same underlying shape: a top-5 global chemicals franchise with intact Gulf Coast ethane cost advantage, a credible $1.5B Value Enhancement Program by 2028, over-delivered cost discipline ($800M on a $600M target in 2025, $1.1B VEP on a $1.0B target), and $8.1B of liquidity cushion, attached to a capital-allocation structure where the $1.7B annual dividend consumes ~74% of 2025 cash from operations and is explicitly under Board review. The committee converges at ~60% base-case probability of survivable cycle recovery, ~25% extended cycle/forced adjustment, ~15% structural-decline tail. The retail Iran-war petchem windfall narrative finds zero support in any filing or transcript and is directionally INVERTED for LYB given its Saudi-upstream Middle East exposure.

Higher Scrutiny RequiredMEDIUM confidence

The committee converged on a middle-band read across every signal: CONDITIONAL revenue, ADEQUATE funding, GAP_EXISTS narrative, MIXED expectations pricing, QUESTIONABLE-leaning-SOUND accounting, DEFENSIBLE (narrowing) moat, ALIGNED governance with NEUTRAL insider signal, MODERATE assumption fragility, MEASURABLE tail risk, FLAGGED consensus blindspot. None alarming in isolation. The simultaneity — particularly the pending February 2026 Board dividend decision, the unresolved $4-5B mid-cycle EBITDA anchor across 5 lenses, the Iran-war narrative inversion specific to LYB's Saudi exposure, and the +40% rally with Access Industries' mid-rally 850k-share trim — warrants deeper investigation before any allocation decision. Corporate survival is robust (>95%); thesis survival at current price is 65-70%. STANDARD_DILIGENCE undersells the shared-assumption fragility. AVOID overstates the tail severity given $8.1B liquidity and intact Gulf Coast franchise. HIGHER_SCRUTINY is the honest reading pending (1) February Board dividend disclosure, (2) Q1 2026 earnings release late April 2026, (3) Chinese NDRC anti-involution formal announcement Q2 2026, and (4) Access Industries subsequent Form 4 sequence.

Key Takeaways

  • REVENUE_DURABILITY is CONDITIONAL: FY2025 $30.15B net sales declined 9.7% against a five-segment diversified book (O&P Americas, O&P EAI, I&D, APS, Technology) with no customer concentration, regulatory loophole, or platform dependency. Management characterizes industry margins at 45% below historical averages — cycle depth, not revenue-model fragility. Q4 2025 segment EBITDA of $417M ($1.7B annualized) is the trough data point.
  • FUNDING_FRAGILITY is ADEQUATE: $8.1B available liquidity, $3.4B cash, $1.5B 2025 bond issuance pre-funding 2026-2027 maturities, 95% cash conversion, interest coverage ~5.1x. Fixed charge math shows $2.89B of annual obligations (net interest + maintenance capex + dividend) against $2.3B CFO — a $590M structural deficit that closes cleanly with a 50% dividend cut. February 2026 Board 'recalibrate' language is pre-cut telegraphing.
  • NARRATIVE_REALITY_GAP is GAP_EXISTS: stock rallied +40% from $57 (Feb 22) to $80 (Mar 31) while management framed 'one of the longest downturns in my career'. Zero Iran/Hormuz commentary in Q4 call, 10-K, or 8-Ks. LYB's Middle East exposure is Saudi-upstream — Hormuz escalation is net-negative operationally, not net-positive. The narrative is inverted for this specific company.
  • EXPECTATIONS_PRICED is MIXED: at $73, implied EV/EBITDA is ~7-8x on a $4-5B mid-cycle EBITDA anchor — DEMANDING for a cycle trough with pending Board decision. The rally is not quite HEAVY because capacity rationalization thesis (23M tonnes claimed, ~10M analyst-verified as named facilities) has genuine supply-side support. The pricing sits between cycle-trough anchor ($57 = ~6x) and cycle-turning multiple ($80 = ~9x).
  • ACCOUNTING_INTEGRITY is QUESTIONABLE-leaning-SOUND: $4.18/share GAAP-to-non-GAAP bridge (GAAP loss $(2.48) → non-GAAP $1.70) is defensible but large. $972M goodwill impairment + $279M other impairments + $52M Q4 LIFO + $61M Q4 identified items are each individually GAAP-compliant. The 2026 capex guide $1.2B below D&A $1.9B relies on 'postponed turnarounds' — one-year discipline, not sustainable.
  • COMPETITIVE_POSITION is DEFENSIBLE: Gulf Coast ethane advantage remains structural (narrower than 2018 peak but intact); vertical integration across olefins/polyolefins/intermediates; proprietary catalyst + polymerization IP; Technology segment ($80M Q4 EBITDA, ~$320M annualized) is countercyclical. MoReTec-1 2027 chemical-recycling startup is a differentiated technology play. Saudi feedstock allocation pre-FID is moat-widening optionality.
  • GOVERNANCE_ALIGNMENT is ALIGNED (with NEUTRAL insider signal): Feb 28 officer grants at $57.52 trough-aligned; zero officer discretionary sales; CEO Vanacker holds 248,554 shares (~$18M at $73). Access Industries (Blavatnik) sold 850k shares on March 9 at $67-69 mid-rally — large strategic-holder trim but only ~5% of direct holdings. Zero active 10b5-1 plans is below industry norm.
  • ASSUMPTION_FRAGILITY is MODERATE and CONSENSUS_BLINDSPOT is FLAGGED: the $4-5B mid-cycle EBITDA anchor is shared across 5 lenses without independent evidence — structural decline to $3-4B would invalidate 5 signals simultaneously. The Iran-war narrative direction is inverted for LYB specifically. Compound downside scenarios aggregate to 25-30%; compound upside 15-20%; asymmetry ~1.5-1.7x.

Key Tensions

  • DEMANDING expectations pricing coexists with DEFENSIBLE moat showing narrowing drift. The compatibility: DEMANDING describes the price demanding cycle recovery to hit $4-5B mid-cycle EBITDA, and narrowing drift is what would prevent that anchor from holding. If the mid-cycle denominator falls to $3-4B, the multiple expands to 10x+ at current price — a different stock.
  • The dividend decision is the load-bearing February 2026 catalyst across four lenses. Stress Scanner math shows a 50% cut saves exactly the identified $590M deficit. Myth Meter flags the cut is not yet priced in at current $73 (retail narrative assumes safety). Roadkill Radar treats a cut as healthy discretionary adjustment. Fugazi Filter sees alignment between Board action and stated 'investment-grade foundation' principle. Convergence on cut expected; market pricing inconsistent with that convergence.
  • Access Industries' March 9 sale of 850k shares at $67-69 is material but adjudicable as NEUTRAL vs. SELLING depending on whether additional Form 4s arrive in the next 60 days. Insider Investigator labels NEUTRAL in isolation; the sequence-or-one-off question is monitored but not yet answered. Blavatnik's legacy position means liquidity management is plausible alongside directional calls — the sale is a data point, not a verdict.
  • Gravy Gauge reads REGULATORY_EXPOSURE as MODERATE because the three open enviro proceedings (Texas AG, TCEQ, Illinois AG) are explicitly non-material per 10-K, while Chinese anti-involution is NET POSITIVE. This is a less cautious read than cycle-heavy peer analyses. The MODERATE label rests on the assumption that Chinese NDRC formal implementation arrives in 2026 — delay would migrate the signal.
  • Fugazi Filter reads GOVERNANCE_ALIGNMENT as ALIGNED based on trough-priced officer grants and zero discretionary sells, while Insider Investigator reads insider signal as NEUTRAL due to zero officer open-market buys at the trough. Both can be true simultaneously: ALIGNED describes structural incentive alignment; NEUTRAL describes trading-signal weight. The absence of officer buying at $57 is modest evidence of no-strong-directional-view, not misalignment.

Gravy Gauge

Is this revenue durable?

About this lens

Key Metrics

Revenue Durability
CONDITIONAL
DURABLE
CONDITIONAL
FRAGILE
ARTIFICIAL
Regulatory Exposure
MODERATE
MINIMAL
MODERATE
ELEVATED
EXISTENTIAL

Key FindingsClick to expand details

Signal AssessmentsClick for full context

SignalAssessment
Revenue Durability
CONDITIONAL
Regulatory Exposure
MODERATE

Model Debates

Cross-Lens Insights

Where Lenses Agree

  • Cycle trough with survivable recovery path at ~60% base-case probability
  • Iran-war petchem windfall narrative has zero filing support and is directionally inverted for LYB
  • February 2026 Board dividend decision is the load-bearing near-term catalyst
  • Value Enhancement Program (VEP) + Cash Improvement Plan (CIP) over-delivery is the credible operational story
  • Mid-cycle EBITDA $4-5B anchor is the single point of maximum assumption fragility

Where Lenses Differ

Accounting Integrity Reading
Fugazi Filter:QUESTIONABLE (elevated diligence)
Gravy Gauge:Non-GAAP bridge is cycle-trough normal

Both can be true simultaneously. The $4.18/share bridge is defensible but large enough that sophisticated readers should focus on $2.5B EBITDA figure rather than $1.70 adjusted EPS.

Governance Alignment vs. Insider Signal
Fugazi Filter:ALIGNED (structural)
Insider Investigator:NEUTRAL (trading signal)

ALIGNED describes structural incentive alignment via trough-priced officer grants and zero discretionary sales. NEUTRAL describes the absence of affirmative open-market buying conviction at the $57 trough.

Expectations Priced Severity
Myth Meter:MIXED (between trough and turning)
Black Swan Beacon:Asymmetry 1.5-1.7x consistent with MIXED, not HEAVY

Both lenses arrive at MIXED via different paths. Myth Meter looks at multiple-on-anchor (~7-8x on $4-5B); Black Swan Beacon looks at scenario probability asymmetry (25-30% downside vs. 15-20% upside).

The following publicly available documents were collected and extracted into a structured fact dossier that powered this analysis.

SEC Filing
  • Annual Report (10-K) — FY2025 (filed 2026-02-20)
  • Quarterly Reports (10-Q) — Q1, Q2, Q3 2025
  • Current Reports (8-K) — 14 filings 2025-01-31 through 2026-01-30
  • Insider Transactions (Form 4) — 22 filings Feb-April 2026
Earnings Transcript
  • Q4 2025 Earnings Call Transcript (2026-01-30)
  • Q3 2025 Earnings Call Transcript
  • Q2 2025 Earnings Call Transcript
  • Q1 2025 Earnings Call Transcript